Page last updated: 2024-11-05

thalidomide and Rosacea

thalidomide has been researched along with Rosacea in 3 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Rosacea: A cutaneous disorder primarily of convexities of the central part of the FACE, such as FOREHEAD; CHEEK; NOSE; and CHIN. It is characterized by FLUSHING; ERYTHEMA; EDEMA; RHINOPHYMA; papules; and ocular symptoms. It may occur at any age but typically after age 30. There are various subtypes of rosacea: erythematotelangiectatic, papulopustular, phymatous, and ocular (National Rosacea Society's Expert Committee on the Classification and Staging of Rosacea, J Am Acad Dermatol 2002; 46:584-7).

Research Excerpts

ExcerptRelevanceReference
"Our findings suggest thalidomide attenuates the inflammation and represses NF-κB activation in skin, which leads to assumptions that thalidomide may be a new therapeutic agent for rosacea."7.91Thalidomide ameliorates rosacea-like skin inflammation and suppresses NF-κB activation in keratinocytes. ( Chen, M; Chen, Z; Deng, Z; Li, J; Liu, T; Peng, Q; Sha, K; Wang, B; Xiao, W; Xie, H; Xu, S; Zhang, Y, 2019)
"Our findings suggest thalidomide attenuates the inflammation and represses NF-κB activation in skin, which leads to assumptions that thalidomide may be a new therapeutic agent for rosacea."3.91Thalidomide ameliorates rosacea-like skin inflammation and suppresses NF-κB activation in keratinocytes. ( Chen, M; Chen, Z; Deng, Z; Li, J; Liu, T; Peng, Q; Sha, K; Wang, B; Xiao, W; Xie, H; Xu, S; Zhang, Y, 2019)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, M1
Xie, H1
Chen, Z1
Xu, S1
Wang, B1
Peng, Q1
Sha, K1
Xiao, W1
Liu, T2
Zhang, Y2
Li, J1
Deng, Z1
Thompson, BJ1
Furniss, M1
Zhao, W1
Chakraborty, B1
Mackay-Wiggan, J1
Qian, G1
Zhou, C1

Other Studies

3 other studies available for thalidomide and Rosacea

ArticleYear
Thalidomide ameliorates rosacea-like skin inflammation and suppresses NF-κB activation in keratinocytes.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 116

    Topics: Animals; Antimicrobial Cationic Peptides; Cathelicidins; Cell Line; Chemokines; Humans; Inflammation

2019
An oral phosphodiesterase inhibitor (apremilast) for inflammatory rosacea in adults: a pilot study.
    JAMA dermatology, 2014, Volume: 150, Issue:9

    Topics: Administration, Oral; Adult; Aged; Female; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors;

2014
Successful treatment of recalcitrant granulomatous rosacea with oral thalidomide and topical pimecrolimus.
    The Journal of dermatology, 2015, Volume: 42, Issue:5

    Topics: Administration, Cutaneous; Administration, Oral; Adult; Drug Therapy, Combination; Female; Humans; I

2015